checkAd

    DGAP-News  562  0 Kommentare Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - Seite 3














    24.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de






























    Language: English
    Company: Biotest AG
    Landsteinerstraße 5
    63303 Dreieich
    Germany
    Phone: 0 61 03 - 8 01-0
    Fax: 0 61 03 - 8 01-150
    E-mail: investor_relations@biotest.de
    Internet: http://www.biotest.de
    ISIN: DE0005227235, DE0005227201
    WKN: 522723, 522720
    Indices: SDAX
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange





     
    End of News DGAP News Service


    Lesen Sie auch



    557735  24.03.2017 




    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - Seite 3 DGAP-News: Biotest AG / Key word(s): Alliance Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) 24.03.2017 / 07:00 The issuer is solely …